Ambrx uses Protein Medicinal Chemistry™ to modify proteins or antibodies to create potentially best-in-class protein therapeutics.
Belrose Pharma focuses on rare diseases and uses its proprietary “releasable linker” conjugation technology and other techniques to improve the clinical efficacy of both novel therapeutics and ...
OPKO-CURNA is developing a unique therapeutic modality focusing on the targeted up-regulation of protein levels via the targeted up-regulation of gene expression.
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technologies. Their integrated platform enables the discovery, design and development of ...
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases
Working to develop the first orally administered integrin therapeutics for patients with immunological, fibrotic, neoplastic, and vascular diseases.
NeuClone works on upstream development of biosimilars including mammalian cell line development and the analytics required to confirm biosimilarity.
Small Molecules, vision and ocular related diseases, and Huntington's disease treatments
Protein Genomics carries out research and development on sophisticated, high performance biopolymers for potential applications in the wound healing, tissue regeneration, dermal filler and ...
The company works on technologies to treat lupus and Sjögren’s disease byremoving inflammatory molecules. Develops Fc - nuclease fusion proteins.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is ...
ZymoGenetics is focused on the discovery and early manufacture of therapeutic proteins.
To be closed in 2019